Status:
UNKNOWN
Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Central Nervous System Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma (DLBCL) entity with a particularly poor prognosis (median survival less than 3 years). They are still poorly characterized bi...
Eligibility Criteria
Inclusion
- Adults
- With a lymphoma of the central nervous system
- Patients having signed the consent for the conservation of their samples within the cohort
Exclusion
- \<18 old years
- Other diagnosis than lymphoma of the central nervous system
- No consent form signed
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2020
Estimated Enrollment :
74 Patients enrolled
Trial Details
Trial ID
NCT03859544
Start Date
January 1 2016
End Date
January 1 2020
Last Update
March 1 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service d'hématologie biologique - Centre Hospitalier Lyon Sud - HCL
Pierre-Bénite, France, 69495